Latest / CME Outfitters Medical Education / Webcast A CaseWise™ Webcast – Precision in Practice: Individualizing FcRn Inhibitor Use in Generalized Myasthenia Gravis
Transcript
- 0:01SPEAKER_07: Hello and welcome.
- 0:02SPEAKER_07: I'm Tony Amato, and I'm going to be moderating today's uh case-wise activity: precision and practice individualizing FCRN inhibitor use and generalized myasthenia gravis.
- 0:14SPEAKER_07: This uh program supported through an independent educational grant from Arginx.
- 0:19SPEAKER_07: And I want to thank uh SAME Outfitters for uh bringing this uh recorded case-wise program uh together.
- 0:26SPEAKER_07: Um, our goal today is practical.
- 0:28SPEAKER_07: We'll use uh three patient uh cases to work through uh diagnostic uncertainty, uh individual individualized FCRN uh treatment selection, longitudinally monitoring when uh the numbers and uh uh patients' uh lived experiences don't agree.
- 0:46SPEAKER_07: Uh before we begin, uh please note that this activity may uh include discussions of products or uses that are not uh currently labeled by the US FDA.
- 0:58SPEAKER_07: Uh when that occurs, we will uh identify the use of any off-label um uh or investigational use.
- 1:08SPEAKER_07: Uh portions of the presentation were developed with the assistance of ChatGPT in keeping with CMT outfitter uh policy.
- 1:17SPEAKER_07: Uh AI-generated material is treated as draft content.
- 1:21SPEAKER_07: Uh the scientific content was independently uh checked and verified against the primary uh sources and reviewed for accuracy, um, fair, balanced, and uh compliance.
- 1:35SPEAKER_07: Uh you'll also see uh AI perspective within each of the cases.
- 1:40SPEAKER_07: Uh, we're using this as another uh perspective to examine, but not as any uh substitute for uh clinical judgment.
- 1:50SPEAKER_07: I'm joined today by two colleagues who uh bring uh complementary perspectives to these cases.
- 1:58SPEAKER_07: Um I will ask them to introduce themselves, uh, beginning with Ketia.
- 2:04SPEAKER_05: Hi, everyone.
- 2:05SPEAKER_05: I'm Ketia Lucima Hibbert.
- 2:07SPEAKER_05: I'm a DNP out of Fort Lauderdale, Florida.
- 2:10SPEAKER_05: I've worked in neurology for the past 16 years.
- 2:14SPEAKER_08: Hi, um, my name is Tuan Vu.
- 2:16SPEAKER_08: I'm a professor of neurology at the University of South Florida in Tampa.
- 2:20SPEAKER_08: I'm also the director of the Neuromuscular Division and the EEG EMG Lab.
- 2:25SPEAKER_08: Uh thank you so much for uh attending this session with us today.
- 2:30SPEAKER_07: Uh thank you.
- 2:30SPEAKER_07: Uh throughout this program, um I want this to feel like a clinical conversation between friends and colleagues.
- 2:38SPEAKER_07: So we'll address each other by uh first names.
- 2:42SPEAKER_07: Um we'll also hear recorded perspectives from Dr.
- 2:46SPEAKER_07: Chris uh Gable and Michael Eyre, um two again experts in myasthenia gravis.
- 2:53SPEAKER_07: The patient's uh voice is built into the cases as well.
- 2:58SPEAKER_07: We will hear from uh Sugani uh Clement Black, uh uh a patient, nurse educator, and patient advocate.
- 3:06SPEAKER_07: Uh her experience is not intended to reproduce the details of uh any one case.
- 3:12SPEAKER_07: It's here to show what the decision decision tree can look like, uh feel like from the patient's side.
- 3:22SPEAKER_07: We have three main objectives, and each case maps directly to one of them.
- 3:28SPEAKER_07: Uh first, recognizing the clinical and diagnostic features that should keep a generalized myasthenia gravis on the table and guide complete phenotyping.
- 3:39SPEAKER_07: Second, individualized FCRN therapy using uh uh product-specific dosing, safety, and uh patient factors.
- 3:48SPEAKER_07: And third, using collaborative monitoring and shared decision-making tools making to connect uh uh symptom fluctuation route, frequency, preference, safety, uh, and goals such as uh minimum minimal um symptom expression.
- 4:08SPEAKER_07: Before we meet our first case, I want to start with the diagnostic journey from the patient side.
- 4:14SPEAKER_07: Listen for the pattern and her symptoms, how they change over the course of the day and with activity, and why the early signs could easily be brushed off by anyone who may not have recognized what was happening.
- 4:29SPEAKER_03: So in the beginning of the day, my symptoms weren't as pronounced as they would be towards the end of the day.
- 4:35SPEAKER_03: So after working a 12-hour shift, um, I I would be literally holding my eye up.
- 4:42SPEAKER_03: I um it almost looked like I had a joker smile, like it was just my teeth, um, and not the corners of my mouth going up.
- 4:52SPEAKER_03: I did try to go work out at times and my arms would be weak.
- 4:58SPEAKER_03: But again, you just you brush it off to something else because when you don't know what you have, you don't you think it could be just like you're having an off day or something?
- 5:12SPEAKER_03: And then as soon as they had put me on um the IVIG when I got admitted, and they had me on prednisone and parietostigmine, my symptoms started to resolve and get better.
- 5:30SPEAKER_07: Uh Tuan, uh what features in what we just heard should keep Myastinia gravis in the differential uh even when the initial presentation doesn't yet have uh uh a clear explanation?
- 5:45SPEAKER_08: I think you know MG is unique in the sense that uh it is fluctuating in nature, and the fatigable weakness is the hallmark of this condition.
- 5:56SPEAKER_08: But uh really very few, if any of them, actually uh can fluctuate.
- 6:02SPEAKER_08: Um so that fact alone point me uh pretty much to my senior gravis, and that's where um I'm gonna be that's gonna be my starting point from where I'm gonna be working from and coming up with the diagnosis.
- 6:15SPEAKER_05: So how she was describing that towards the end of her work day, she had extreme limitation um with um her vision and terms of how she's able to navigate.
- 6:28SPEAKER_05: Um, she had more fatigue.
- 6:30SPEAKER_05: So that would lead me to believe that it's myestinia gravis because that's a hallmark feature that as the day progresses, the symptoms worsen because of the overuse of the muscles.
- 6:43SPEAKER_07: Well, that's great.
- 6:43SPEAKER_07: And uh that brings us to our first case.
- 6:46SPEAKER_07: The central question uh in this case is diagnostic.
- 6:49SPEAKER_07: What should happen when a phenotype looks like myastinia gravis, but the initial acetylcholine receptor antibody uh result is negative.
- 6:58SPEAKER_07: So in this first case, Beverly is 42 and is referred to a community neurologist after six months of fluctuating weakness.
- 7:07SPEAKER_07: Her story includes intermittent phosis and double vision, difficulty chewing through a full meal, occasionally coughing with water, nasal speech after prolonged conversation, arm fatigue with routine activities such as uh washing or combing her hair.
- 7:25SPEAKER_07: The pattern matters.
- 7:27SPEAKER_07: Symptoms are milder in the morning, worse with repetitive activity, and partially improved with rest.
- 7:35SPEAKER_07: A prior MRI scan of the brain was unrevealing, an acetylcholine receptor binding antibody was negative.
- 7:44SPEAKER_07: She was told myasthenia was unlikely and that anxiety or occupational stress might be contributing.
- 7:52SPEAKER_07: She's now worried about worsening swallowing symptoms, um, but she's reluctant to miss more work uh for another evaluation that may be called normal.
- 8:06SPEAKER_07: On exam, the pattern continues.
- 8:08SPEAKER_07: She has ptosis that increases with sustained upgaze, double vision with sustained upgaze, mild eye closure weakness on exam, increased nasal speech with prolonged counting, fatiguable neck and proximal arm weakness, distill muscle strength, sensation, reflexes, and gait are normal.
- 8:30SPEAKER_07: She does not appear in any respiratory or ventilatory distress and is managing her uh secretions.
- 8:41SPEAKER_07: So this is where the gap becomes clear.
- 8:44SPEAKER_07: Um prior evaluation stopped after a single negative acetylcholine receptor binding um antibody result.
- 8:52SPEAKER_07: Uh musk antibodies, LRP4 testing was not done.
- 8:57SPEAKER_07: We don't have uh either evidence of a modulating antibodies uh or blocking antibodies being done on the acetylcholine uh receptor, also.
- 9:08SPEAKER_07: Uh there was no repetitive stem or single fiber exam done, uh no neuromuscular referral was arranged.
- 9:16SPEAKER_07: Uh her diagnostic evaluation is therefore incomplete, um, and thus no generalized myasthenia gravis directed therapy was initiated.
- 9:30SPEAKER_07: Based on uh what you know at this point, what would be the next step uh in uh advancing uh uh the diagnostic evaluation of Beverly?
- 9:42SPEAKER_07: Uh please go ahead and make your decisions.
- 10:03SPEAKER_07: But before we share outside perspectives, I want each of us on the record uh with an immediate next step.
- 10:10SPEAKER_07: Uh Twine, uh what would you do next?
- 10:13SPEAKER_08: Uh looking at the uh clinical picture, uh this is a uh purely uh motor uh disorder, and the characteristic that separates this from everything else is basically the fluctuation of symptoms.
- 10:28SPEAKER_08: Uh of all the choices that were given, uh the one that uh make most sense to me would be uh C, uh ordering the MUSC antibodies, um, arrange for photodiagnostic testing and um facilitate a neuromuscular specialist referral.
- 10:45SPEAKER_07: And Kenya, what do you think?
- 10:48SPEAKER_05: I agree with Dr.
- 10:49SPEAKER_05: Vu, and I would also initiate pyrogristamine um under the suspicion that this is generalized myosenior gravis, therefore to offer a treatment that could be therapeutic and diagnostic as we continue uh to do further work up.
- 11:05SPEAKER_07: Yeah, I I I like that too.
- 11:07SPEAKER_07: I agree with both, and I do agree.
- 11:10SPEAKER_07: Now let's uh hear how our uh community uh clinicians would approach the same uh case.
- 11:17SPEAKER_02: The patient lives 75 miles from the neuromuscular center and does not want to miss more work.
- 11:22SPEAKER_02: A periodystigmine trial is inexpensive and familiar, and a good response supports the diagnosis while I hold further testing in reserve.
- 11:30SPEAKER_02: My struggle is that my EMG lab has a long wait list, and my schedule is booked months out.
- 11:35SPEAKER_02: I know A and B are wrong and D goes too far.
- 11:39SPEAKER_02: I worry though that a partial response could delay a confirmed diagnosis.
- 11:44SPEAKER_01: In my setting, I am the referral, so I would draw musk antibodies and do repetitive nerve stimulation and single fiber EMG if needed in one visit so she misses as little work as possible.
- 11:56SPEAKER_01: I would also get a baseline FEC and give her clear red flags because emergency care is far away.
- 12:02SPEAKER_01: My struggle with option E is logistics.
- 12:05SPEAKER_01: It's tempting to spare her the travel, but deferring confirmation in a bull bar patient far from an ICU is the wrong trade.
- 12:15SPEAKER_07: Next, we'll hear the perspective from our contributing myasthenia gravis expert, Dr.
- 12:20SPEAKER_07: Carissa Gable.
- 12:23SPEAKER_04: I'm Dr.
- 12:23SPEAKER_04: Carissa Gable.
- 12:24SPEAKER_04: I am a neuruscular medicine specialist at Duke University, and I'm going to discuss some of these cases today.
- 12:30SPEAKER_04: At this point, I think do uh C, which is order musk antibody testing, arrange targeted electrodiagnostic testing for neuromuscular junction disorder, and facilitate neuromuscular specialist referral.
- 12:42SPEAKER_04: Um so in this case, reassuring the patient that autoimmune MG has been excluded because the acetopoline receptor binding in a body was negative is not completely correct.
- 12:50SPEAKER_04: She could have musk positivity, she could still be SIRA negative, but have myoscinia.
- 12:56SPEAKER_04: Um, so that's incorrect.
- 12:58SPEAKER_04: Um, waiting for six months to look for SIR conversion, which does happen in the first six months through a year, um, is not an adequate uh next step for a diagnosis.
- 13:08SPEAKER_04: Um and then uh just going ahead and diagnosing SRA negative myosinia without doing any further testing isn't really recommended because you don't quite have a definitive diagnosis until you can at least show that it's musk positive, in which case it might dictate different treatment options versus um, you know, like just initiating treatment um without a clear diagnosis is usually not recommended.
- 13:34SPEAKER_04: And then if you started protostigmine for suspected genitalized MG and she had uh musk myoscinia, she'd actually might have an adverse reaction to that.
- 13:42SPEAKER_04: So she needs further testing.
- 13:45SPEAKER_07: And finally, here's a perspective from our contributing uh genites myasthenia graphis, Dr.
- 13:51SPEAKER_07: Michael Hare.
- 13:53SPEAKER_06: Hi, my name is Mike Hare.
- 13:55SPEAKER_06: I'm a neuromuscular neurologist at the University of Vermont, um, where I also serve as the um vice chair of clinical affairs.
- 14:05SPEAKER_06: Um and I am a clinical researcher uh for patients with myasthenia gravis.
- 14:11SPEAKER_06: So I think my preferred answer is a combination of three answers or three answers, but I think primarily C, they're presenting the classical clinical presentation of generalized myastenia gravis with fatiguable ocular bulbar and limb weakness.
- 14:30SPEAKER_06: And in this circumstance, acetylcholine receptor binding antibody is negative.
- 14:35SPEAKER_06: The next step in a patient's evaluation in this circumstance would be to check for um anti-MUSC antibodies.
- 14:43SPEAKER_06: I would proceed with rather urgent electrodiagnostic testing in this patient's case.
- 14:49SPEAKER_06: Because we don't know the patient's MUSC antibody status, it would be difficult to know which agent to choose first in this patient, but I would consider starting both a combination of acetylcholinesterase inhibitor and possibly an immunotherapy given the severity of this patient's presentation and my suspicion that this could be generalized myestin and gravis.
- 15:12SPEAKER_06: Um, I don't know if I would go directly to an FCRN inhibitor because I don't know what form of myestin this is.
- 15:21SPEAKER_07: We gave the same uh case and answer uh choices to ChatGPT without adding additional information beyond the case.
- 15:30SPEAKER_07: The AI selected the option that broadens antibody testing, obtains neuromuscular junction-focused electrodiagnostic testing, and facilitates a neuromuscular uh referral, just like um uh our experts all did and my colleagues.
- 15:46SPEAKER_07: A useful question um is not whether AI matches the answer key, it's whether uh the reasoning recognizes uh the limitations of one uh negative antibody result and avoid prematurely prematurely labeling uh Beverly as being uh seronegative myasthenic.
- 16:05SPEAKER_07: We've now heard clinicians and AI interpret the decisions.
- 16:09SPEAKER_07: Now let's return to the patient perspective.
- 16:12SPEAKER_07: Listen to what happened after neurology referral was placed, how delays in getting the specialty evaluation affected her uh diagnostic journey.
- 16:24SPEAKER_03: After I first was tested to see if I had MG, before that we did an MRI.
- 16:32SPEAKER_03: Um, they did CT scans, different things to make sure I didn't have a stroke or anything else.
- 16:39SPEAKER_03: The hardest thing was getting into see a neurologist, even though you had that referral, it was like weeks were going by and I wasn't getting a callback, or um they want to like schedule you a month out, and it's like you're struggling, which I ended up being hospitalized because my symptoms got worse.
- 17:02SPEAKER_03: So that's my diagnosis came from my hospitalization.
- 17:08SPEAKER_03: I would have loved when I first was tested and the I knew the referral was sent to neurology.
- 17:16SPEAKER_03: I would have loved for neurology to be more reactive and like calling me back or getting me an appointment.
- 17:28SPEAKER_07: Well, that um that was uh eye-opening, huh?
- 17:32SPEAKER_07: We've we've heard that um in our clinic patients too when we've uh uh when we see them for the first time through their journey.
- 17:40SPEAKER_07: Kedia, I mean again, I think this is an important reminder that placing referral is not uh the necessarily the end of the process when the clinical picture remains concerning and symptoms of are progressing.
- 17:52SPEAKER_07: Uh what should the care of the team uh be to make sure the referral leads to a timely evaluation?
- 17:58SPEAKER_05: Yes, I agree.
- 17:59SPEAKER_05: Putting the referral is the beginning of that portion and um making sure that the individuals that are responsible and making sure that it can be carried out, whether there's barriers in insurance or is there delays in terms of availability for the patients to get on the schedule, um, it's making sure that all the key stakeholders are involved and working as a multidisciplinary team to ensure that the referral is properly handled, the patient is seen in a timely fashion, and um the results can be um given to the patient in a true time.
- 18:37SPEAKER_07: I agree 100%.
- 18:40SPEAKER_07: Again, a key principle here is a negative acetylcholine receptor antibody test um should not end a walkup.
- 18:47SPEAKER_07: Uh, again, when that clinical phenotype is still strongly suggestive of mycinia gravis.
- 18:54SPEAKER_07: And uh the evaluation needs to go through at least four different actions or phases.
- 19:00SPEAKER_07: You need to know and understand the pattern, broaden the uh antibody evaluation, get electrodiagnostic confirmation, and refer uh when the workup cannot be completed locally, uh, or when the uh clinical severity really requires it.
- 19:21SPEAKER_07: So we uh need to separate um what's established from what is being studied.
- 19:26SPEAKER_07: The registrational FCRN uh evidence uh generated with uh established myasthenia graphists who are relatively uh stable background uh therapy, adapt early trial, um is is studying a different question in a newly acetylcholine receptor positive disease, uh, and there is no efficacy or safety results uh to apply to Beverly today.
- 19:53SPEAKER_07: Beverly is not yet at a treatment selection decision, her diagnosis is incomplete.
- 20:00SPEAKER_07: Current phenotype includes uh ball bar and proximal features, the clinical pattern remains concerning to all of us, uh, and uh the workup needs to move.
- 20:13SPEAKER_07: So here's a cross-section how different perspectives uh have been answered.
- 20:18SPEAKER_07: Our survey data reinforce that this is not an isolated problem.
- 20:22SPEAKER_07: Nearly half the rep responding HCPs identified uh tri attribution to anxiety, depression, deconditioning as a contributor to the delayed or missed diagnosis.
- 20:35SPEAKER_07: Well, patients commonly reported being told they were simply tired or being out of shape.
- 20:40SPEAKER_07: This is the gap that Beverly represents.
- 20:44SPEAKER_07: So let's bring the perspectives together.
- 20:46SPEAKER_07: The first question is where the diagnostic process failed.
- 20:50SPEAKER_07: Was the main air a negative acetylcholine receptor antibody results, or what happened after it?
- 20:58SPEAKER_07: Uh Tuan, uh you previously raised an important uh practical question here.
- 21:04SPEAKER_07: Uh, when your suspicion is high, uh, do you uh prefer uh a broader antibody uh testing up front or a sequential approach?
- 21:15SPEAKER_08: Um my approach is is uh certainly mine, and and people have you know feel free to do things differently.
- 21:24SPEAKER_08: Um but I agree with you that that you know the highest possibility here, diagnostic possibility here is my senior avis.
- 21:32SPEAKER_08: And um some people would prefer to do it sequentially, but but personally I like to shotgun it.
- 21:39SPEAKER_08: Uh the other thing is that if you look at the natural history of MG patients, uh the first two or three years are going to be the toughest.
- 21:47SPEAKER_08: They're gonna be rapidly progressing from you know baseline, which is no symptoms, to their maximum uh severity.
- 21:55SPEAKER_08: And if you prolong this diagnostic process by doing sequential testing.
- 22:00SPEAKER_08: You're gonna waste several months, uh, if not longer.
- 22:04SPEAKER_08: And uh that's an important point here.
- 22:06SPEAKER_08: So that's why uh at this point I would go ahead and do uh the ol three subtypes of ACH or antibodies, uh the MUSC and the RRP4 as well, and then go from there.
- 22:20unknown: Yeah.
- 22:21SPEAKER_07: I'll ask, do you do LRP4?
- 22:23SPEAKER_07: I I I'll be honest, I it is a little controversial, isn't it?
- 22:29SPEAKER_07: And so some people wonder, I mean, so it probably is a very, very small percentage, but you know, I think it's personally I don't always get that.
- 22:43SPEAKER_08: Um I I think that I get it for the simple reason that some I agree, you know, it's it's seen in ALS and other conditions, so it requires you to have that um uh suspicion um that it's just MG and not something else.
- 22:58SPEAKER_08: You can't just do the antibody and call it uh MG if it's just LRP4.
- 23:04SPEAKER_07: Very good, thank you.
- 23:05SPEAKER_07: I think the main uh point is uh just because you have a uh acetylcholine receptor negative test does not mean one that they don't have myasthenia, but it's also doesn't imply um seronegative.
- 23:20SPEAKER_07: I think the the big issue that I see is I want to know if it's uh if it's a MUSK case.
- 23:26SPEAKER_07: Because uh a MUSK um treat treatment strategies can differ if if they're a MUSK case.
- 23:46SPEAKER_08: My personal experience is that if you have um uh ACHR antibodies or uh MUSK antibodies, you almost don't need uh you know electrodiagnostic.
- 23:59SPEAKER_08: Um there's very few people that have the antibodies, those two antibodies, and don't have symptoms.
- 24:05SPEAKER_08: However, if you have the RRP4s or the uh triple sero negative, uh you have to make sure that these patients actually have MG and not something else.
- 24:14SPEAKER_08: And that's when I would rely on single fiber or rep stem to um make the diagnosis.
- 24:21SPEAKER_07: I think one concern people is single fiber can be so sensitive, so you get a false positive.
- 24:28SPEAKER_08: Yeah, that's that's the real thing.
- 24:29SPEAKER_07: So and so you could have a non-myasthenic person that's weak for another neuromuscular reason and have uh um uh uh uh abnormal jitter on a single fiber.
- 24:42SPEAKER_07: So that's a whole nother uh conversation.
- 24:45SPEAKER_07: One final point uh anxiety and stress can coexist with any neurological disease as as we all know.
- 24:53SPEAKER_07: Um in a patient with fluctuating uh fatigable phenotype.
- 24:57SPEAKER_07: Uh you'd have to treat the attribution of coexistent anxiety or stress um as as a possibility, not the main cause of the symptoms, um, and not let that be the uh endpoint of the uh diagnostic workup.
- 25:15SPEAKER_07: Before we leave Beverly, let's pull this case together.
- 25:18SPEAKER_07: Let's go back to our learners.
- 25:20SPEAKER_07: And after we've all heard the discussions, uh now what would you do next?
- 25:44SPEAKER_07: So our second case moves from diagnosis to treatment selection.
- 25:49SPEAKER_07: So Marcus uh is a 58-year-old uh man with acetylcholine receptor generalized positive uh positive myocene gravis.
- 25:58SPEAKER_07: He remains symptomatic despite prentosone, mycrophenylate, and parietal stigmine treatment.
- 26:04SPEAKER_07: He has arm and neck fatigue late in the day, difficulty chewing through a full meal, intermittent uh slurred speech uh after a prolonged conversation.
- 26:17SPEAKER_07: Pentasone um is having its own side effects.
- 26:22SPEAKER_07: He's had weight gain, worsening uh uh blood glucose control, problems sleeping, uh uh easy bruising, and he wants to reduce these cortical steroid uh dose to reduce these side effects.
- 26:40SPEAKER_07: His preferences are not all pointing in one direction, however.
- 26:44SPEAKER_07: He wants fewer clinic visits, is apprehensive about self-injections, values predictabil predictable control, uh, works a full-time job, and has limited flexibility uh for recurring weekday appointments.
- 27:04SPEAKER_07: His MG ADL score is six, generalized myasthenogravis score is twelve, immunoglobulin level is within the laboratory reference range, his complete blood count and comprehensive metabolic profile do not show any um clinically significant abnormalities.
- 27:23SPEAKER_07: On examination, he has fatigable tois, he has neck flexion weakness, weakness in his proximal arms.
- 27:33SPEAKER_07: Diagnosis is well established by the positive acetylcholon receptor antibody testing and with repetitive nerve stimulation.
- 27:45SPEAKER_07: This slide um adds the practical constraints.
- 27:49SPEAKER_07: Marcus is already on 20 milligrams of prednisone daily, myclophenylate, one gram twice a day, and parietal stigmine.
- 27:59SPEAKER_07: He has not had meningococcal vaccination um series, um, vaccination series as yet.
- 28:06SPEAKER_07: He lives 70 minutes from the nearest infusion center.
- 28:11SPEAKER_07: His spouse can assist him though at home if need be.
- 28:16SPEAKER_07: The clinical signal is uh persistence symptoms despite adequate conventional steroids.
- 28:24SPEAKER_07: And the cortical steroids that he's giving is giving him side effects.
- 28:30SPEAKER_07: Any next option must uh be evaluated against the route setting the cadence, safety requirements, vaccination um status, and what Marcus uh really wants and can realistically uh sustained.
- 28:52SPEAKER_07: Which approach most appropriately guides selection amongst the available FCRN targeted therapies for Marcus?
- 29:21SPEAKER_07: So before we hear from uh external perspectives, let's each state the approach that we would use uh for Marcus.
- 29:30SPEAKER_05: So um, based off the Marcus's clinical picture, I would select to do D, a subcutaneous FCRN targeted therapy, because when we're taking into consideration of compliance with treatment, we obviously want it to be the appropriate treatment based off diagnosis, um, but ensure that the patient is able to adhere to the treatment plan because it won't disrupt uh their day-to-day.
- 29:57SPEAKER_08: I think D is a really reasonable um choice.
- 30:01SPEAKER_08: However, um what um prevent me from choosing that is that um he is not keen on giving himself injections.
- 30:09SPEAKER_08: I think E is a sort of a more broad um uh answer and may cover all bases.
- 30:18SPEAKER_08: Um because you know he wants constant, really good control.
- 30:23SPEAKER_07: I kind of agree that D hearing about his concerns is probably gonna be um if I was asked, I would be telling him I think that might be the best choice for him.
- 30:38SPEAKER_07: But again, I don't like to choose for a patient, so I probably um I would go through all the options like like E, but I think ultimately D for him might be best if he could get over the injection part.
- 30:53SPEAKER_07: So now let's hear how our community clinician uh weighed the same constraints.
- 31:00SPEAKER_00: FCRN agents differ in indication, route, who administers them, cyclic versus continuous dosing, and monitoring.
- 31:08SPEAKER_00: So I would match those differences to his stated priorities.
- 31:12SPEAKER_00: For example, the F.
- 31:13SPEAKER_00: Gartigamod subcutaneous pre-filled syringe can be given by a patient or caregiver after training, which fits his home life, while nipocalamab is a provider-administered IV infusion every two weeks, which offers predictable dosing, but more trips.
- 31:27SPEAKER_00: Options A, B, and D each optimize a single variable.
- 31:31SPEAKER_00: Option C leaves him on toxic prednisone with an MGADL of six after three years of mycophenylate.
- 31:37SPEAKER_01: The patient is 70 minutes from an infusion center and cannot take recurring weekday time off.
- 31:43SPEAKER_01: Subcutaneous dosing at home, with his spouse trained to inject, removes the biggest barrier, and in my practice, access determines adherence.
- 31:53SPEAKER_01: My struggle is that I know E is the textbook answer, but I start with what the patient can actually get to.
- 31:59SPEAKER_01: A continuous IV regimen would mean roughly 26 round trips of 140 minutes each per year.
- 32:08SPEAKER_07: Let's hear our first KOL perspective on Marcus.
- 32:12SPEAKER_07: Dr.
- 32:13SPEAKER_07: Gable.
- 32:15SPEAKER_04: I think probably in this case, the best answer might be E.
- 32:20SPEAKER_04: So selecting an SGM retargeted therapy after comparing product-specific indications, rehouse administration setting, dosing cadence, CT requirements, and his treatment priorities, which are that he doesn't want to give himself injections, but he does have a spouse who's willing to assist.
- 32:34SPEAKER_04: So there are options for that for home therapy that would not require clinic visits.
- 32:41SPEAKER_04: So I think that would be something to discuss here.
- 32:44SPEAKER_04: Picking just a subcutaneous therapy because of fewer clinic visits, that is not so specific.
- 32:51SPEAKER_04: So there are some fewer ones that you can give yourself, but I think it's more comprehensive to kind of go through all the options with the patient.
- 32:59SPEAKER_04: So there's some shared decision making on what would be the best for him.
- 33:02SPEAKER_04: So I think E is still like the better choice here.
- 33:04SPEAKER_04: So he's indicated that he doesn't want to give himself injections, but wants less of a burden of treatment.
- 33:09SPEAKER_04: Um he still has a lot of generalized symptoms, relatively high MGADL score, um, despite being on mycophenylate and prednisone and has a lot of side effects from the prednisones.
- 33:21SPEAKER_07: Very good.
- 33:22SPEAKER_07: And let's hear from our second expert, uh, Dr.
- 33:25SPEAKER_07: Hare.
- 33:27SPEAKER_06: I think I would choose some form of cancer E, but I do think that in this case, the patient requires escalation of therapy.
- 33:38SPEAKER_06: Um, this person is still symptomatic on a combination of um higher dose prednisone and mycophenylate.
- 33:47SPEAKER_06: Um, and I think adding a another agent would be appropriate in this circumstance.
- 33:54SPEAKER_06: I think one could choose an FCRN inhibitor um for a patient like this one.
- 34:01SPEAKER_06: I think it would be equally appropriate uh to choose a complement C5 inhibitor in a patient like this one.
- 34:08SPEAKER_06: I think it would be also somewhat reasonable to consider a B cell inhibitor in this patient's case as well.
- 34:15SPEAKER_06: So I think any one of those three could be reasonable.
- 34:19SPEAKER_06: Uh, but the key in this person's circumstance is escalating therapy.
- 34:23SPEAKER_06: In addition, uh considering escalation of therapy in this patient, he is younger than age 65 with significant symptoms.
- 34:32SPEAKER_06: Um, so it and is within three years of onset.
- 34:36SPEAKER_06: So I do think it is appropriate to consider referral for a discussion of uh thymectomy in this case, done under camera guidance as part of the overall treatment plan at this moment.
- 34:49SPEAKER_07: So ChatGPT also looked at the options and uh selected again a systemic comparison approach rather than choosing a um any specific uh um uh single approach.
- 35:04SPEAKER_07: Now let's hear directly from the patient's perspective about what mattered uh most when choosing the treatment, uh where the convenience fit into that decision.
- 35:15SPEAKER_03: I just wanted anything that was gonna work and give me my life back, um, so you could have some normalcy because I had gotten to the point where um over the last probably the last two years were my worst, where I was doing plasma phrases.
- 35:33SPEAKER_03: Um, we started doing plasma phrases uh every other week, and it was almost like I just I had still became so weak.
- 35:43SPEAKER_03: I have respiratory failure as my disease progressed.
- 35:47SPEAKER_03: So I'm on a non-invasive ventilator.
- 35:49SPEAKER_03: Um, so I never really thought about the convenience of anything.
- 35:54SPEAKER_03: I just wanted something that was gonna work and give me my life back and have some normalcy.
- 36:00SPEAKER_03: And that's what the medication I'm on now has done for me.
- 36:04SPEAKER_03: I literally was willing to do anything I could.
- 36:07SPEAKER_03: If somebody told me it was gonna work, I would have tried it.
- 36:10SPEAKER_03: So I convenience wasn't a factor to me.
- 36:15SPEAKER_07: So that's an important reminder to all of us not to assume that uh treatment convenience carries the same weight uh for every individual patient.
- 36:24SPEAKER_07: For Tigani, I was finding a treatment that uh worked and helped her uh regain some uh normal n normality in her life um outweighed uh concerns about convenience.
- 36:37SPEAKER_07: Marcus told us that uh fewer visits mattered to him and that he was apprehensive about uh self-injections, but we still need to understand how he weighs uh these considerations against disease control and uh other treatment factors.
- 36:54SPEAKER_07: Uh Kenya, how would you ask uh Marcus what uh matters most to him before uh finalizing uh um his treatment?
- 37:05SPEAKER_05: So I would ask Marcus what is the goal in terms of his treatment plan?
- 37:10SPEAKER_05: Would he just want to achieve um better day-to-day quality as it pertains to the limitations of what the Maya Senior Gravis is giving him, or would he just prefer to have reduced um fluctuation, uh, which may mean uh that he would go into an office setting.
- 37:30SPEAKER_05: So understand what is his goals and his treatment plan, uh, provide him with all the options so we can do shared decision making and what would be most um effective and appropriate for him.
- 37:44SPEAKER_07: Very good.
- 37:45SPEAKER_07: So here's the response pattern across groups.
- 37:48SPEAKER_07: The survey uh data add an important patient perspective here.
- 37:52SPEAKER_07: Patients prioritize uh strength, fatigue, symptom stability more often than simply having a treatment that fit their schedule.
- 38:01SPEAKER_07: Um, that reinforces why we can't choose for Marcus based on convenience alone.
- 38:07SPEAKER_07: The distinction um is what we want to resolve is uh uh that in the final discussion.
- 38:15SPEAKER_07: Much of what we use in a routine uh uh myocinea gravis care is are guidelines or uh consensus-driven approaches uh that do not necessarily um carry uh FDA-labeled uh indication uh in the same way as uh the approved drugs uh in the table um uh are shown.
- 38:41SPEAKER_08: The uh FDA labeled treatment categories uh shown here include pyridostigmine and three targeted classes, uh CD19 directed B cell therapy, Kalman inhibition, and FCRN antagonism.
- 38:54SPEAKER_08: Uh that distinction, conventional versus targeted and guideline versus uh FDA labeled, is the organizing principle of this slide.
- 39:04SPEAKER_08: Uh from here, we will focus more closely on the FCRN antagonists while keeping the appropriate comparators in view.
- 39:14SPEAKER_07: Yeah, I I would just say the uh the table um kind of uh reinforces that there are a number of options that we have uh when we approach patients uh that that are kind of FDA approved, but uh uh as we've mentioned, there are there are uh non-fda uh medications that are commonly used.
- 39:38SPEAKER_07: And again, we have to discuss all of these uh with our patients and and help uh help them decide what best uh option uh there is for them.
- 39:50SPEAKER_08: So this is one of the diseases that I think uh is is really fun to treat, mainly because of all the options and all the uh different factors you have to uh take into consideration to come up with the best diagnosis.
- 40:04SPEAKER_08: So it's challenging.
- 40:06SPEAKER_08: At the same time, it's uh very intellectually uh stimulating.
- 40:11SPEAKER_07: I agree.
- 40:11SPEAKER_07: I love taking care of myasthenia for that reason.
- 40:13SPEAKER_07: You can really change their life.
- 40:15SPEAKER_05: Yes.
- 40:16SPEAKER_05: Because the chart helps also for patients to understand if they're part of patient support groups or if they have loved ones, you know, the Facebook groups and things like that, like, oh, I heard somebody's on this treatment.
- 40:29SPEAKER_05: This is a nice snapshot of everything that we can have a discussion and really for like patient advocacy groups of possible um treatment options for patients.
- 40:38SPEAKER_07: So adding to what you said is yeah, I've had patients, you know, if if if I have a patient who's concerned about that, and and ask them um if they'd want to talk to one of my patients who have offered to talk to other patients about their experience has been with myasthenia and and the in the different drug options, and um, that can be very helpful from hearing from other patients.
- 41:04SPEAKER_07: So so I just want to briefly just summarize how FCRN receptors work.
- 41:10SPEAKER_07: FCRN normally rescues uh immunoglobulin from lysosomal degradation, f CRN antagonism interferes with this recycling process, so uh more IgG is routed and degraded um to the lysosome.
- 41:27SPEAKER_07: So, again, these myastinia graphics antibodies um are depleted.
- 41:32SPEAKER_07: So, Ketty, in a patient like Marcus, um, how should treatment uh access and the um burden influence uh the choice amongst uh available approaches, including travel, the site of care, vascular access issues, uh, and administration uh requirements?
- 41:51SPEAKER_05: I think having those um that as a discussion piece when talking about treatment options um helps the patients feel at ease if they know that they are not going to be disrupted in their day-to-day.
- 42:06SPEAKER_05: Um, if a patient has to consider their work schedule and um calling off for work for certain days, is that going to be a financial burden and how that will play into their um adherence to the treatment plan?
- 42:21SPEAKER_07: So here's a table where um uh the FDA FDA approved FCRN antagonists.
- 42:28SPEAKER_07: And so as you can see, um the route, the schedule, administrative settings, uh, and monitoring requirements uh differ.
- 42:39SPEAKER_08: I would start by saying that that MG patients are unique.
- 42:44SPEAKER_08: Each one of them is a little bit different.
- 42:46SPEAKER_08: Some patients will um do well with one cycle and don't need the next cycle for a couple months.
- 42:53SPEAKER_08: Um so cyclical treatment makes perfect sense for those patients, so they don't have to be on uh regular treatment uh until they need it.
- 43:02SPEAKER_08: Um on the other end of the spectrum, you have patients that that continuously need something to keep the symptom in check.
- 43:10SPEAKER_08: Uh so now you have the option of, you know, every two weeks with nipocalam.
- 43:16SPEAKER_08: Um with f gottigamod, you can actually use it in cycles, and you can determine how long between cycles you can use.
- 43:25SPEAKER_07: I think that was kind of an important thing you mentioned was that yeah, uh FGOctigamod uh was approved issue with the adapt trial, so they got four weekly injections, and then they would have to wait four weeks and some some could wait four weeks, some could wait longer, and you kind of did it when they um started getting worse.
- 43:45SPEAKER_08: Yeah, I think I think you know the original idea that uh you give the patient the option of you know having treatment when they want to and and not having it when they don't need to, it is uh really good on paper.
- 43:57SPEAKER_08: But in my personal experience, once the Patient get better, they do not want to get worse again before they get better.
- 44:03SPEAKER_08: So, you know, initially when we uh when this medication first came out, that's that's the uh you know that's the problem we face, where the patient just calls you and say, hey, I'm getting worse again, give me the next cycle, kind of thing.
- 44:17SPEAKER_08: Um so now that we have a couple of years of experience behind us, you know, we we feel less uh insecure about giving the next cycle uh sooner.
- 44:29SPEAKER_08: Um but you know, at the at the other end of the spectrum, there's a patient that doesn't need a cycle except twice a year.
- 44:37SPEAKER_08: And that's great as as well.
- 44:39SPEAKER_07: Kenny, what do you have any thoughts on on the slide?
- 44:43SPEAKER_05: No, I agree.
- 44:45SPEAKER_05: Um now that we have more real-world um experience, uh the apprehensiveness of staying very close to the study design, because that's as clinicians we're trained, you want to follow the study design as it was um approved and as you get more comfortable, and then the conversations you have with the patient.
- 45:05SPEAKER_05: So then you can decipher, because as Dr.
- 45:07SPEAKER_05: Vu stated earlier, every patient is a very different, unique uh perspective.
- 45:14SPEAKER_07: Very good.
- 45:16SPEAKER_07: So the next next slide, um, it's not um a head-to-head comparison uh of the different um inhibitors, but and you can't really because it's different treatment populations in the research study, some different endpoints, dosing, uh analysis.
- 45:33SPEAKER_07: But the important uh point to bring out here is that um uh each of these uh FCRNs has evidence supporting the its labeled use.
- 45:44SPEAKER_07: Um but it the numbers in the separate trial, you can't really rank them uh one against each other um when you're when you're comparing efficacy.
- 45:55SPEAKER_07: Um uh toine, I mean what what would you um uh how would you interpret again this slide or what want patients to uh or clinicians to know from this slide and patients.
- 46:10SPEAKER_08: Yeah, so that's the problem with clinical trials, right?
- 46:12SPEAKER_08: You have a very selected population, um, and your criteria for success is different.
- 46:19SPEAKER_08: And then um if you look at each study, uh they have a collection from you know a participant from across the world in different countries, and in each country you have uh different use of background therapy.
- 46:35SPEAKER_08: So uh as a result, you cannot compare one study to the other because they're of all these differences.
- 46:43SPEAKER_08: Um so you know the thing is is you have to choose, uh and they've all been proven via uh you know phase three trials um to have efficacy.
- 46:56SPEAKER_08: So you just have to pick one, uh one that fits your patient's situation the best and go with it.
- 47:02SPEAKER_08: Um we we still uh don't have a lot of data um in terms of intra class switching.
- 47:10SPEAKER_08: Um so uh you know, so we can we can't say that that you know if if the patient uh does didn't respond to class uh to drug A, they would probably do with better with drug B or C.
- 47:24SPEAKER_08: We don't have that data.
- 47:26SPEAKER_08: Um we don't have head-to-head data to to make that uh decision or switch.
- 47:31SPEAKER_07: Good.
- 47:31SPEAKER_07: And and I and I'd add to the same principle applies also when looking at safety and tolerability, um and how we compare you know safety and tolerability across these um uh various studies and uh advance adverse events that may have occurred during the clinical trials.
- 47:51SPEAKER_07: Uh so I mean Keddy, uh uh um how does uh reliable safety uh uh workflow look like um um before the first dose and between um doses?
- 48:04SPEAKER_05: Well, as a part of the workup and the shared decision, when we decide on what treatment option that the patient's gonna proceed, um, you want to make sure that the patient is aware of safety signals that was presented throughout the clinical trials.
- 48:19SPEAKER_05: So uh making sure that the patients are aware of that, um, and then constantly through the follow-up, you're inquiring about what has been reported and looking to see if there's anything new.
- 48:31SPEAKER_05: Um, if the patient is at baseline, not experiencing any of the common reported adverse effects.
- 48:39SPEAKER_05: You want to make sure that the patient and the caregiver is well informed and knows to notify the clinical team.
- 48:45SPEAKER_07: Uh very good.
- 48:47SPEAKER_07: Um so again, Marcus uh should not be treated as an FCRN only decision.
- 48:53SPEAKER_07: Uh the question is uh where an FCRN strategy fits relative to optimization of conventional therapy.
- 49:01SPEAKER_07: Um, IVIG and plasma exchange are useful when you again you want to get rapid uh short-term control.
- 49:09SPEAKER_07: Um and we also need to consider other treatments like complement inhibit inhibition and B cell directed therapy.
- 49:18SPEAKER_07: As we uh briefly discussed um uh earlier, uh the the meningococcal vaccination schedule needs to be considered.
- 49:28SPEAKER_07: I mean, you have to keep on top of getting vaccines.
- 49:31SPEAKER_07: It's not one, it's not a one and done, and that takes uh time and effort and uh recording or when they're due.
- 49:39SPEAKER_07: Um again, it's it's advised to wait uh till they complete the first six months of vaccination schedule, but it's not um it's not uh mandated.
- 49:53SPEAKER_07: Again, if a patient needs it and you think it's the best option, um you can certainly uh uh start the vaccination and start the complement inhibit inhibition, but they need to be on anti-prophylactic uh medications.
- 50:10SPEAKER_07: Uh again, I I asked you about this before, but maybe reiterate again.
- 50:16SPEAKER_07: Um uh when you um compare the different medications, uh what are the variables uh that uh might uh mean the most to you and and maybe Marcus?
- 50:29SPEAKER_08: Yeah, I think if you go back to Marcus, uh his um you know uh primary goal is to be able to have good control so that he can uh stay employed and have fairly low treatment burden and he doesn't want to do any sort of self-injection.
- 50:46SPEAKER_08: So um certainly the uh some of the compliment inhibitors will allow that.
- 50:52SPEAKER_08: Um you know, some of them give you a very long interval between treatment, so that that's uh a good choice.
- 51:01SPEAKER_08: So the other option for low treatment burden uh would be the B cell directed therapy, and and they require uh you know free treatment every six months, so that's a good choice.
- 51:13SPEAKER_08: Um but like I mentioned before, the the problem here is that he's already on two uh immunosuppressant, and adding a third one may increase uh his risk of infection um potentially significantly.
- 51:29SPEAKER_08: Uh, so that should be taken into consideration as well.
- 51:33SPEAKER_08: Um but on the other hand, you you have all these options and uh it's sort of uh you know rely on you to uh it's um to decide which way you do and and how you do it.
- 51:46SPEAKER_05: So treatment selection almost never happens in one visit with one clinician.
- 51:52SPEAKER_05: Rather than treating this as a checklist, I would walk it in a way that the patient moves through care in four stops from left to right.
- 51:59SPEAKER_05: First, confirm candidacy.
- 52:02SPEAKER_05: This usually starts with neurologists or neuromuscular specialists, uh, which could be an advanced practice provider that is in the same office as a neurologist or a neuromuscular specialist.
- 52:16SPEAKER_05: Second, fit the plan to daily life.
- 52:18SPEAKER_05: How far is the drive?
- 52:20SPEAKER_05: Can the patient step away from work?
- 52:22SPEAKER_05: You want a third, plan administration.
- 52:25SPEAKER_05: Who gives the treatment?
- 52:27SPEAKER_05: The patient, the caregiver, or the clinician, and what training is required?
- 52:32SPEAKER_05: Will there be requirement of ongoing reinforcing education to ensure that the patient understands how to administer to limit site injection reaction, um, making sure that the administration happens properly, uh, because sometimes we hear that the patient had held the device in the wrong manner and they injected the wrong way.
- 52:54SPEAKER_05: Um, fourth, you would like to protect and monitor.
- 52:58SPEAKER_05: Review vaccination and prophylaxis when relevant.
- 53:02SPEAKER_05: Uh, define how response will be measured and decide whether improved control permits corticor steroid reduction.
- 53:09SPEAKER_07: What's the danger of choosing a product for Marcus because one feature looks attractive?
- 53:15SPEAKER_07: One.
- 53:16SPEAKER_08: In a situation like this where we have a lot of good options, um definitely a shared decision-making process is important.
- 53:25SPEAKER_08: You have to take into consideration consideration his work and lifestyle, and how do you, you know, tailor the treatment to meet his needs.
- 53:34SPEAKER_08: And I think that's probably the most important factor in maintaining compliance uh with treatment.
- 53:41SPEAKER_08: Um and this is a evolving process, uh, it's not a one-time uh deal kind of thing.
- 53:49SPEAKER_08: So, you know, you have to negotiate what you need at the moment, what will fit your needs, and as we control the disease, uh the symptoms better, what change and how do we adjust uh to that?
- 54:03SPEAKER_07: And Marcus is clinically very um symptomatic despite being on adequate doses uh of steroids, and he's having steroid toxicity.
- 54:14SPEAKER_07: Uh so um how does that influence um your decision in um reassessing or escalating treatment?
- 54:23SPEAKER_08: I am not a fan of steroids, and I avoid it when uh possible.
- 54:27SPEAKER_08: We don't look at the long-term uh consequences.
- 54:30SPEAKER_08: Um there are certainly studies showing that even low dose of steroid over a number of years will increase the risk of um hypertension, cardiac uh diseases, obesity, diabetes, and so on.
- 54:44SPEAKER_08: Um so we just basically kick the can down the road in terms of of cost.
- 54:50SPEAKER_08: And Marcus, I think, demonstrates that point um in the fact that he has, like you said, thyroid toxicity, and therefore we should try to minimize that.
- 55:00SPEAKER_07: Yeah.
- 55:00SPEAKER_07: And Kedia, can you bring us back to the patient?
- 55:03SPEAKER_07: Which of Marcus's practical constraints actually becomes uh clinical variables?
- 55:09SPEAKER_05: So having a subcutaneous FCRN um that will eliminate needing to call off from work, um, utilizing PTO time or sick time or FMLA paperwork, which adds stress on both parties, the patient as well as the clinic, um, in terms of turnaround and having that available, um, and travel in distant times.
- 55:31SPEAKER_07: So let's recap Marcus.
- 55:33SPEAKER_07: Where was the gap?
- 55:34SPEAKER_07: What changed the decision, and what would you do differently uh with the next patient who looks like him?
- 55:59SPEAKER_07: Our final case asks a different question.
- 56:02SPEAKER_07: What do you do when a treatment is clearly helped, but the disease scores uh look reassuring, but the patient still cannot uh live the life she is trying to get back.
- 56:16SPEAKER_07: Mai is 35, works as a high school counselor.
- 56:19SPEAKER_07: Six months ago she began uh cyclic substance FCRN uh regimen.
- 56:25SPEAKER_07: Her visible myasthenia gravis symptoms improve substantially.
- 56:29SPEAKER_07: Uh she needs no rescue therapy or emergency care and complete her um basic self-care independently.
- 56:37SPEAKER_07: But she still develops uh disabling fatigue after four or five hours of work.
- 56:42SPEAKER_07: She's had to reduce her work uh schedule to four days a week, no longer participates in evening school events, often needs prolonged recovery after a full workday.
- 56:54SPEAKER_07: She noticed symptoms uh become uh more um apparent after completing a treatment cycle before the next cycle begins.
- 57:03SPEAKER_07: Uh clinic administration requires time away from work.
- 57:08SPEAKER_07: Her goal is a full-time school day, uh, a full school work, and regular participation with family and social events.
- 57:19SPEAKER_07: On brief examination, Maya looks substantially better than she did before treatment.
- 57:23SPEAKER_07: There's notosis at rest, no bull bar weakness, no respiratory um distress.
- 57:30SPEAKER_07: She has only mild fatigue of bulltosis and uh proximal arm fatigue ability with sustained activity.
- 57:37SPEAKER_07: She's had no recent infections, um no uh medication side effects, uh no acute exacerbations of her myasthenia gravis.
- 57:50SPEAKER_07: Her uh MGADL score improved from an eight to one, QMG score improved from a 13 to 5.
- 57:59SPEAKER_07: She's needed no rescue therapy.
- 58:04SPEAKER_07: Keep in mind uh uh one interpretive question uh as you look at these numbers.
- 58:10SPEAKER_07: Uh if uh she reports that the end of uh cycle worsening uh when the treatment cycle uh is where MG A uh MGADL and uh QMG uh is measured, how should that uh timing affect what you would uh conclude from the scores?
- 58:32SPEAKER_07: Uh Maya remains um in the prescribed uh cyclic FCRN regimen.
- 58:38SPEAKER_07: Uh uh also takes uh prednisone 5 milligrams daily and parietal stigmine as needed.
- 58:45SPEAKER_07: Subsequent cycles are based on clinical evaluation.
- 58:49SPEAKER_07: Her symptoms become more noticeable after a cycle and before the next cycle.
- 58:55SPEAKER_07: Uh treatment uh currently is administered in a clinic, which requires her to miss part of her work day.
- 59:03SPEAKER_07: So we have three things going on at once objective improvement, yet residual function impairment, and superimposed on this is the treatment delivery burden.
- 59:17SPEAKER_07: So which step uh uh most appropriately um aligns with the ongoing management uh with uh Maya's uh treatment response and goals?
- 59:48SPEAKER_05: So I would choose A because as we've already um discussed, um, when it comes to subjective fatigue, there's not instruments that we have that can help us really guide.
- 1:00:00SPEAKER_05: But um I would make sure that I would kind of stick with A in reassessing the MG activity, even though objectively she may appear to be better, um, but um subjectively she's really struggling.
- 1:00:15SPEAKER_08: Yeah, I I agree with Katie.
- 1:00:16SPEAKER_08: I I would pick A as well for for the very reasons that she just described.
- 1:00:21SPEAKER_08: It give you the a broader, more gestalt approach to her problems than just focusing on one.
- 1:00:29SPEAKER_07: And I agree.
- 1:00:31SPEAKER_07: You know, let's hear our how our uh community clinician would approach the same uh patient.
- 1:00:39SPEAKER_00: Her scores show an excellent objective response, yet her fatigue is disabling and worsens near the end of each cycle.
- 1:00:46SPEAKER_00: I need to separate end-of-cycle MG fluctuation from sleep, mood, deconditioning, and steroid effects, and to address her treatment burden.
- 1:00:54SPEAKER_00: A pre-filled syringe for self-injection is now approved, so she may not need to miss work for clinic visits.
- 1:01:01SPEAKER_00: Option C, before a full assessment, may treat the wrong problem, and the safety of starting a new cycle sooner than four weeks after the last dose has not been established.
- 1:01:11SPEAKER_00: Option B lets good scores hide real disability, and option D discards a clear responder's therapy.
- 1:01:18SPEAKER_02: Maya's MGADL fell from eight to one, and her QMG from 13 to 5 with no rescue therapy, so by standard measures, she is a responder.
- 1:01:27SPEAKER_02: I would continue therapy and monitor.
- 1:01:30SPEAKER_02: The problem is that in a 15-minute visit, scores are what I can document, and I have no quick clinic tool for fatigue.
- 1:01:36SPEAKER_02: I recognize that the scores may miss what matters the most to her.
- 1:01:43SPEAKER_07: And next we'll um hear how our uh first KOL perspective, uh Dr.
- 1:01:48SPEAKER_07: Gable, uh, would approach this.
- 1:01:52SPEAKER_04: So I think the most appropriate answer here is A, is to reassess her activity, her fatigue pattern, her quality of life, other contributors, treatment burden, and kind of reassess the goals after modifying therapy.
- 1:02:04SPEAKER_04: So you wouldn't want to just keep on the current FCRN regimen and just tell her she's fine because that's not really fair because she's still having a lot of impact on her day-to-day life.
- 1:02:12SPEAKER_04: Um similarly, you wouldn't want to just go back to the prior therapy.
- 1:02:16SPEAKER_04: I mean, this therapy and this mechanism of therapy seems to be working for her.
- 1:02:20SPEAKER_04: It's just not optimized.
- 1:02:21SPEAKER_04: Um, you could shorten the interval between the treatment cycles so she does have a wearing off effect.
- 1:02:26SPEAKER_04: Um, but there is some treatment burden with this particular FCRN treatment.
- 1:02:30SPEAKER_04: So there might be some other options for her that might suit her lifestyle better.
- 1:02:33SPEAKER_04: So that's why A is like a more appropriate response, I think.
- 1:02:37SPEAKER_04: Um and then, yeah, again, just continuing the current FCRN regimen and going to primary care evaluation for causes of fatigue.
- 1:02:45SPEAKER_04: Um, she has other features on the clinical exam and uh and other kind of issues along with the treatment burden that are still demonstrating that she could optimize treatment here.
- 1:02:55SPEAKER_04: So I think that's why A is the correct answer.
- 1:02:59SPEAKER_07: And let's hear from Dr.
- 1:03:01SPEAKER_07: Eyre.
- 1:03:03SPEAKER_06: I think in this circumstance, I think I would um primarily choose choice E.
- 1:03:14SPEAKER_06: Um, I think it would be appropriate to help assess for other causes of fatigue along with the primary care um clinician in this case, given that uh the patient's weakness seems to be quite improved on the current immunotherapy strategy and peritostigmine with the primary symptom of fatigue, not fatiguable weakness, I'd be concerned that there could be a secondary cause of that symptom in a patient like this one.
- 1:03:47SPEAKER_06: And then one would think about other potential causes of fatigue, um, such as an under or untreated mood um disorder.
- 1:03:58SPEAKER_06: So I think thinking broadly about this patient before escalating immunotherapy would be important.
- 1:04:06SPEAKER_07: ChatGPT uh selected a broad assessment before modifying therapy.
- 1:04:10SPEAKER_07: The reasoning was a MI has had a meaningful objective response, but residual fatigue and functional impairment still needs to be characterized.
- 1:04:19SPEAKER_07: Let's hear what uh meaningful control sounds like uh from the patient side.
- 1:04:26SPEAKER_03: What would be ideal for me is to continue to feel normal where you are walking up the stairs and you don't feel like your body is like lead.
- 1:04:36SPEAKER_03: Like you can just go right up those stairs.
- 1:04:39SPEAKER_03: You don't have to think about each step along the way, or having somebody to help you, or having to hold on to somebody um not being on the oxygen um and or just doing little things like a few weeks ago, I was able to wash the windows in my house.
- 1:04:58SPEAKER_03: And I know it sounds like something so trivial, but I haven't been able to do that in two years, things like that.
- 1:05:05SPEAKER_03: You know, just living again.
- 1:05:08SPEAKER_03: I think that's the key is to just have as much as much function as you can.
- 1:05:13SPEAKER_03: Um, for me, my ADL score was 15 before, and now it's a three.
- 1:05:20SPEAKER_03: Like I never in a million years would have thought over the last year I could get it that low again.
- 1:05:26SPEAKER_03: Um, so things like that have been amazing.
- 1:05:31SPEAKER_07: So it stands out is improvement is not just a lower score.
- 1:05:35SPEAKER_07: Um uh it's uh being able to uh climb stairs, do things around the house, get back to everyday life.
- 1:05:42SPEAKER_07: So uh for my uh my other question is whether improvement on uh on the scores uh translates to a functional improvement that matters to her.
- 1:05:52SPEAKER_07: Um Kedia, uh what would uh you document after a conversation like this uh with the patient?
- 1:05:59SPEAKER_05: What I would take away in terms of what the patient described is that she was able to achieve better function in her life.
- 1:06:11SPEAKER_05: So knowing that at the beginning of her journey, prior to starting this new targeted therapy, she was scoring MG ADL of 15 and it got down to three.
- 1:06:21SPEAKER_05: And recalling that within her journey, she had to utilize oxygen and having so much impairment and now having better quality of life.
- 1:06:31SPEAKER_05: Not only have we helped her achieve the goals that she was desiring, but also mentally, when we think about how this disease has probably plagued her due to all of the progression and then the missteps.
- 1:07:16SPEAKER_07: The question is whether our assessments, again, we do is measuring what the patient is trying to regain.
- 1:07:25SPEAKER_07: These treatment factors don't disappear once an initial treatment is chosen.
- 1:07:32SPEAKER_07: Antibody status, stability, safety, administration burden, work and travel schedule, caregiver support, costs, and their preference need to be revisited over time, particularly according to the response and as circumstances might change.
- 1:07:56SPEAKER_07: So, Ketty, one question before we move to the measurement framework.
- 1:08:01SPEAKER_07: If reassessment confirms that FCRN therapy remains effective, but the treatment administration is contributing to Maya's work burden, how might the administration setting or the patient or caregiver administrator option affect the plan?
- 1:08:19SPEAKER_05: I would have that conversation with her to let her know there is the option of a subcutaneous FCRN that can be self-administered at home and bringing in caregiver if necessary if she doesn't feel comfortable injecting herself, and having the support of not only the clinical team but also from the support team of the company to provide a nurse for education, re-education if necessary, if the confidence is not there, especially in the beginning of the treatment plan.
- 1:08:53SPEAKER_05: Sometimes the patients need that extra support.
- 1:08:56SPEAKER_07: Katia, can you walk us through what we should be reassessing with patients on their visits?
- 1:09:05SPEAKER_05: None of these instruments captures fatigue as a distinct construct.
- 1:09:09SPEAKER_05: What is exactly my problem, and we must discuss about the endurance across a full day, recovery time, and work capacity directly.
- 1:09:18SPEAKER_05: To detect, you must measure treatment success, pairs, disease control with symptom state, functional goals of the patient considers acceptable.
- 1:09:28SPEAKER_05: A stable score is not enough on its own.
- 1:09:39SPEAKER_07: This slide kind of makes it more explicit.
- 1:09:43SPEAKER_07: And Aketi, can you speak a little more to this?
- 1:09:47SPEAKER_05: The neurologist or the neuromuscular specialist, um, either a nurse practitioner or PA also can own the diagnosis, phenotype, and more detailed objective assessment, therapy, or retreatment decisions.
- 1:10:01SPEAKER_05: The APP can own interval MG ADL and quality of life capture, fluctuation history, goal review, and escalation when scores or symptoms worsen.
- 1:10:12SPEAKER_05: The pharmacy reviews interactions, vaccination, cumulative immunosuppression, and drugs that may worsen MG.
- 1:10:21SPEAKER_05: The infusioner, the specialty nursing, owns the administration tolerance, training where the label supports it, primary care helps evaluate sleep, mood, endocrine, hematologic, and other contributors while continuing preventative care.
- 1:10:37SPEAKER_05: If the function worsens, goals are unmet, or bobar and respiratory symptoms emerge, the next person should not have to guess who needs to know.
- 1:10:46SPEAKER_05: And that's why it's important as a multidisciplinary approach when you have all of these clinicians with the patient's outcome at mind, making sure that they have the best outcome, that we work in tandem.
- 1:11:00SPEAKER_07: So let's uh close the loop on uh on the on the reasoning.
- 1:11:05SPEAKER_07: Uh again, there's different perspectives on how we interpret uh Maya's uh concurrent symptoms and the disconnect what we might see um from the scores uh that we that we obtained, and then how really um Maya is still impaired in certain functions.
- 1:11:26SPEAKER_07: Twan, uh you previously mentioned how we can simply shorten the interval um of uh administration uh to maybe try to ease the b burden of of Maya's uh uh having to come to the clinic.
- 1:11:41SPEAKER_07: And and given this, how how might the uh recent labels uh that um caregivers can um um get administer the drug or the patient can do self-administered with uh uh uh prefilled syringes?
- 1:11:57SPEAKER_08: Before answering that question, I think uh is often obvious to me that Maya actually have two issues.
- 1:12:05SPEAKER_08: Um number one is that she has recurrent symptoms uh sooner uh than the next cycle.
- 1:12:14SPEAKER_08: So shortening the cycle certainly would help that uh problem.
- 1:12:19SPEAKER_08: And like you said, there's now pre-fuel syringes where the patient can sell administered you know 60 to 90 seconds, um, and that's not a problem.
- 1:12:30SPEAKER_08: Um so the the second issue here is that she complained of a lot of fatigue, and the fatigue unfortunately is not well measured by our instruments.
- 1:12:45SPEAKER_08: So, for example, the MGADL talk a lot about um activity of daily living, and you can see in this case she went from an eight to a one and would qualify for minimal symptom expression, and yet she still continued to be uh debilitated by the fatigue.
- 1:13:03SPEAKER_08: So, in cases like this, and I have cases like this, uh you have to think outside the box and see what else is contributing.
- 1:13:10SPEAKER_08: Um, in somebody who has been on steroid a long time, they may have um obesity and extra weight to carry around, and then that can cause fatigue.
- 1:13:20SPEAKER_08: Um, depression is not uncommon in patients with MG, and that's certainly one of the main drivers of uh psychological uh burden, anxiety, fatigue, and so on.
- 1:13:33SPEAKER_08: So that needs to be explored and treated.
- 1:13:36SPEAKER_08: Um and sleep apnea is not uncommon in these patients, and so um, and then of course, you know, steroids and other metabolic abnormalities, vitamin B12 deficiency, and so on.
- 1:13:47SPEAKER_08: So all those things have to be taken into uh consideration and excluded to improve her overall status uh and not just simply uh shorten some cycles, um, which solve one problem but not the other.
- 1:14:02SPEAKER_08: Um so the important thing is we we do these scores, uh, but we need to know uh where they fit in.
- 1:14:09SPEAKER_08: So obviously the score in the middle of a cycle is going to be different than the score before the next cycles, um, especially with cyclical treatment.
- 1:14:20SPEAKER_08: Um so you have to sort of pick a point where um you measure the same score at each time, um, and uh so that you can make meaningful um adjustment rather than you know looking at different things at different times and and and try to change the the outcome.
- 1:14:40SPEAKER_05: And then we want to make sure that we don't just approach it where it's just one um clin clinical group that is looking at um her concerns because despite the treatment plan, if she's concerned about her fatigue, we need to have a collaborative effort of not only the neurology providers, but also primary care and other uh stakeholders that can improve her outcome.
- 1:15:08SPEAKER_07: Good.
- 1:15:08SPEAKER_07: Uh so let's rediscuss um Maya, like we uh have already for Beverly and Marcus.
- 1:15:14SPEAKER_07: Hers is a case where the numbers look reassuring, yet she's still struggling.
- 1:15:20SPEAKER_07: Um to plainly state it, there's a gap.
- 1:15:23SPEAKER_07: Uh a big takeaway um is ask oh um what the score does not capture and then reassess um these uh goals as uh uh explicitly as uh uh scores.
- 1:15:38SPEAKER_07: So now we can answer the same question, what would you do next?
- 1:16:01SPEAKER_07: Across the three cases, the actions are deliberately concrete.
- 1:16:05SPEAKER_07: First, complete the phenotype when the uh clinical um pattern remains convincing rather than allowing a negative result to close the loop and the workup.
- 1:16:16SPEAKER_07: Second, do a systemic comparison of the indication, the dosing, the route, the safety, and patient circumstances before selecting a target of therapy.
- 1:16:29SPEAKER_07: Third, pair validated myasthenia gravis scores with the patient stated goals and lived functioning when we're seeing them back in follow-up and deciding whether the control is adequate.
- 1:16:46SPEAKER_07: Those are the three behaviors we want uh to carry uh back into our practices.
- 1:16:53SPEAKER_07: Additional clinical resources from uh CME Outfitters are available on the CME Outfitter website.
- 1:17:01SPEAKER_07: You can also visit the CME Outfitter Virtual Education Hub uh for additional certified education and clinical resources.
- 1:17:12SPEAKER_07: To receive CME or CE credit, please complete the post-test and evaluation online.
- 1:17:19SPEAKER_07: You will then be able to download um your certificate.
- 1:17:23SPEAKER_07: I want to really thank Kedia and uh Tuan for the thoughtful discussions, uh, to our contributing um KOLs and community clinicians, uh, especially to Tigani for uh sharing uh patient perspective.
- 1:17:43SPEAKER_08: Thank you very much for joining us.
- 1:17:45SPEAKER_08: Uh we really appreciate your attention.
- 1:17:48SPEAKER_07: Thank you so much.
- 1:17:49SPEAKER_07: Thank you all.
- 1:17:50SPEAKER_07: It was it was great working with you on this.
- 1:17:53SPEAKER_07: Thank you.
- 1:17:54SPEAKER_07: Thank you.